Tolerability of abacavir in the clinical setting.
Martín-Carbonero
L
L
Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.
Barreiro
P
P
Soriano
V
V
González-Lahoz
J
J
D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D004357:Drug Synergism; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019055:No-Observed-Adverse-Effect Level; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012449:Safety; D000099227:Abacavir
D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir